Skip to main content
Journal cover image

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.

Publication ,  Journal Article
Fogelman, D; Sugar, EA; Oliver, G; Shah, N; Klein, A; Alewine, C; Wang, H; Javle, M; Shroff, R; Wolff, RA; Abbruzzese, JL; Laheru, D; Diaz, LA
Published in: Cancer Chemother Pharmacol
September 2015

PURPOSE: Metastatic pancreatic adenocarcinoma is considered a uniformly fatal disease with a median survival of 1 year with modern chemotherapy. While a subset of patients achieve prolonged survival, few of the factors that define this group of patients are known. METHODS: For the determination of overall survival (OS), 549 patients with histologically confirmed metastatic pancreatic adenocarcinoma were evaluated. Emphasis was placed on treatment history and family history of breast, ovarian, and pancreatic cancers. To ensure a uniform metastatic population, patients treated with prior locoregional therapies (i.e., surgery or radiotherapy) were excluded as were patients with a prior history of stage I-III disease. RESULTS: Patients with family history or pedigree history of cancer had superior OS. This was especially true in patients with three or more relatives with either breast, ovarian, or pancreatic cancers [hazard ratio (HR) 0.49, 95 % confidence interval (CI) 0.30-0.80, p = 0.003]. First-line platinum chemotherapy was associated with a poor survival (hazard ratio for death 1.74, 95% CI 1.12-2.71, p = 0.01) for patients without a family history of these cancers but not for those without such a history (p = 0.31). In fact, as the number of relatives with these cancers increased, the OS survival improved for individuals receiving first-line platinum therapy (HR 0.76, 95 % CI 0.65-0.89, p = 0.0004), which was not the case for those receiving other therapies (p = 0.98). CONCLUSIONS: Treatment with platinum chemotherapy in patients with a family history of breast, ovarian, or pancreatic cancers was associated with a longer survival, whereas platinum use in patients without such a family history of cancer was associated with poor survival. These findings suggest that family history may serve as a predictive marker for platinum use in patients with metastatic pancreatic adenocarcinoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Chemother Pharmacol

DOI

EISSN

1432-0843

Publication Date

September 2015

Volume

76

Issue

3

Start / End Page

489 / 498

Location

Germany

Related Subject Headings

  • United States
  • Survival Analysis
  • Pancreatic Neoplasms
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fogelman, D., Sugar, E. A., Oliver, G., Shah, N., Klein, A., Alewine, C., … Diaz, L. A. (2015). Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol, 76(3), 489–498. https://doi.org/10.1007/s00280-015-2788-6
Fogelman, David, Elizabeth A. Sugar, George Oliver, Neeraj Shah, Alison Klein, Christine Alewine, Huamin Wang, et al. “Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.Cancer Chemother Pharmacol 76, no. 3 (September 2015): 489–98. https://doi.org/10.1007/s00280-015-2788-6.
Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep;76(3):489–98.
Fogelman, David, et al. “Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.Cancer Chemother Pharmacol, vol. 76, no. 3, Sept. 2015, pp. 489–98. Pubmed, doi:10.1007/s00280-015-2788-6.
Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep;76(3):489–498.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

EISSN

1432-0843

Publication Date

September 2015

Volume

76

Issue

3

Start / End Page

489 / 498

Location

Germany

Related Subject Headings

  • United States
  • Survival Analysis
  • Pancreatic Neoplasms
  • Organoplatinum Compounds
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Humans
  • Female